Thursday 16 October, 2025
Objectives: To develop population pharmacokinetic model for methotrexate (MTX) in patients with acute lymphoblastic leukaemia (ALL), receiving high-dose MTX followed…
Read morePoster: Applications- Oncology
Modeling of the metastatic variability in cancer disease.
Thursday 16 October, 2025
Objectives: In cancer diseases the appearence of metastases is a very pejorative forecast. In a first time we shall show…
Read moreAnalysis of Biomarker Responses in Phase I Study of rhIL-18 in Combination with Rituximab in Non-Hodgkin’s Lymphoma to Support Phase 2 Dose Selection
Thursday 16 October, 2025
Objectives: The safety and biological activity of the combination of recombinant human interleukin-18 (rhIL-18) in combination with rituximab is currently…
Read morePopulation Pharmacokinetics of 5FU and its Major Metabolite 5-FDHU in Colorectal Cancer Patients
Thursday 16 October, 2025
Objectives: Develop a population pharmacokinetic model for both 5-fluorouracile (5FU) and 5-fluoro-5,6-dihydrouracil (5-FDHU) to explore mechanisms and factors affecting 5-FU metabolism….
Read morePharmacokinetics of paclitaxel and its metabolites using a mechanism-based model
Thursday 16 October, 2025
Objectives: The influence of the genotypes of the metabolizing enzymes, CYP2C8 and CYP3A4 on the clearance of paclitaxel are still…
Read moreA mechanism-based model for the population pharmacokinetics of aflibercept in healthy subjects
Thursday 16 October, 2025
Objectives: Aflibercept (VEGF-Trap), a novel antiangiogenic agent that binds to VEGF, has been investigated for the treatment of cancer [1,2]….
Read moreEvaluating the Extent of Chemotherapeutic Contamination from Central Venous Catheters in Children with Cancer and Providing Guidance for Accurate Reporting of PK Parameters
Thursday 16 October, 2025
Objectives: To support the use of a clearing procedure that minimizes catheter contamination when a single central venous line (CVL)…
Read moreLeukopenia following high-dose chemotherapy with autologous stem cell retransfusion in patients with testicular cell cancer
Thursday 16 October, 2025
Objectives: Myelosuppression is one of the most important dose-limiting adverse events in many anticancer regimens. In a clinical study 19…
Read moreData mining analysis of survival data in cancer of pancreas : first exploratory step for identification and validation of explicative variables
Thursday 16 October, 2025
Objectives: Pancreatic cancer is a relative sparse pathology with few Evidence Base Medecine. Given the rapid progression of the disease,…
Read moreModelization of bevacizumab effect on tumour perfusion assessed by Dynamic Contrast Enhanced Ultrasonography
Thursday 16 October, 2025
Objectives: Bevacizumab (Avastin®) is an angiogenesis inhibitor. Its clinical efficiency in the treatment of solid tumour in association with classical…
Read more